Table 1 Reversion mutations (variant allele fraction > 0.5%) conferred resistance to PARPi resistance

BRCA1

Q1756fs*74 (c.5266dupC)

Q1756_D1757 > PG (c.5263_5272 > TCCCCAGGAC)

3.2%

HGPSC^a

BRCA1

1479delAG (c.1360_1361del)

s454_l467del (c.1361_1402del)

TNBC^b

BRCA2

K2162fs*5 (c.6486_6489delACAA)

K2150fs^a17 (c.6448_6473del26)

8%

mPC^c

BRCA2

V1283fs*2 (c.3847_3848delGT)

D1280_N1288del (c.3838_3864del27)

33%

57%

Breast cancer

BRCA2

V1804Kfs (c.5410_5411del)

Y1480_A1896del (c.4434_5686delinsTT)

0.60%

mPC^c

BRCA2

V1804Kfs (c.5410_5411del)

I1633_I2269del (c.4897_6807del)

0.40%

2.80%

mPC^c

BRCA2

Q2960X (c.9106C > T)

Q2960E (c.9106C > G)

67%

Breast cancer

BRCA2

E1493Vfs*9 (c.4705_4708delGAAA)

I1490_E1493del (c.4698-4709delAAATACTGAAAG)

55–56%

HGPSC^a

BRCA2

S1982fs (c.5946delT)

S1982_ A1996del (c.5946_5990del45)

1%

Prostate cancer

BRCA2

S1982fs (c.5946delT)

S1985fs (c.5949_5952dupAAAA)

0.5%

Prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

A1843_S1985del (5528_5956del429)

0.53%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

A1891_M1936del (5671_5808del138)

0.54%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

D1909_D1911 > EDY (5727_5731TAATG > AGACT)

0.63%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

L1908_S1917del (5721_5750del30)

1.8%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

N1766_Q2009del (5292_6025 > CA)

1.3%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

N1910_D1911del (5728_5733delAATGAT)

3.3%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

S1788_P2114 > DTT (5362_6340 > GATACCA)

1.2%

prostate cancer

BRCA2

N1910fs*2 (5727_5728insG)

NA (splice site 5333_6841 + 197del1706)

4.8%

prostate cancer